Description

This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as add-on therapy to background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).